Breaking News!

QuantiVirus™ MPXV Test Kit has been granted with FDA EUA for Monkeypox virus detection

Press Release

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

Transforming Cancer Care with

SPOT ON Precision Diagnostics

Press Release

DiaCarta to Become a Publicly Listed Company

Through Merger with HH&L Acquisition Co.

Press Release

DiaCarta Receives CE-IVD Mark for Its

SARS-CoV-2 Flu A/B Combo Test

Press Release

DiaCarta’s Multivariant COVID-19 Test

Accurately Detects the Omicron Variant

Media Coverage by Genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay

to Gauge Chemotherapy Response

in Multiple Cancers

Breaking News!

QuantiVirus™ MPXV Test Kit has been granted with FDA EUA for Monkeypox virus detection

Press Release

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

Press Release

DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co.

Press Release

DiaCarta Receives CE-IVD Mark for Its SARS-CoV-2 Flu A/B Combo Test

Press Release

DiaCarta’s Multivariant COVID-19 Test Accurately Detects the Omicron Variant

Media Coverage by genomeweb

SARS-CoV-2 Delta Variant PCR Could Help Surveillance Efforts, Developers Say

Media Coverage by genomeweb

DiaCarta Positioning Liquid Biopsy Assay to Gauge Chemotherapy Response in Multiple Cancers

DiaCarta is a leading translational genomics and personalized diagnostics company based in Pleasanton, California with significant business operations in China. DiaCarta provides highly sensitive and advanced technologies that will change the landscape of precision medicine and molecular diagnostics by impacting healthcare treatment plans and the well-being of individuals around the world.

HPV mRNA Screening

NGS Targeted Sequencing

CLIA Lab Service

ULTRA-SENSITIVE

XNA Technology

XNA, xenonucleic acids, are innovative new nucleic acid molecular oligomers that hybridize by Watson-Crick base pairing to target DNA sequences, and yet have a modified chemical backbone. XNA oligomers are highly effective at hybridizing to targeted normal DNA sequences and can be employed as molecular clamps in quantitative real-time polymerase chain reactions (qPCR) or as highly specific molecular probes for the detection of nucleic acid target sequences. The XNA tightly binds to the wild-type sequence that is 100% complementary and blocks DNA polymerase from DNA elongation; only the mutant target sequence gets amplified because the XNA:mutant DNA duplex is not stable due to mismatch and fall off from the template in PCR reactions.

ULTRA-SENSITIVE

SuperBDNA™ Technology

SuperbDNA™ technology uses branched DNA to qualitatively or quantitatively measure the presence of target DNA or RNA. Unlike PCR or RT-PCR, SuperbDNA™ technology does not amplify the DNA or RNA in the samples, rather amplifies the signals for detection. Because the amplified signal is proportional to the levels of the target (DNA or RNA) in the samples, the latter is easy to be quantified with a standard curve. SuperbDNA™ technology has been used in FDA-approved clinical applications, including prognosis and monitoring of patients with viral diseases. 

DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit

DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its QuantiVirus™ MPXV test, which is a PCR test for the qualitative detection of DNA from monkeypox virus (MPXV) in lesion swabs collected from individuals suspected of monkeypox infection.

DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience

DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, and Nonagen Bioscience Corporation (“Nonagen”), a cancer diagnostics company, today announced the successful completion of the validation study of Oncuria® multiplex bladder cancer immunoassay as a laboratory developed test (“LDT”). DiaCarta also announced that it has begun receiving patient urine samples for testing in its CLIA certified lab in Pleasanton, California.

Early Cancer Detection Will Save More Lives

Cancer deaths due to failure of early detection According to the American Cancer Society researchers, it is estimated that there will be more than 600,000 people die of cancer, and 1.9 million new cancer cases in the US in 2021 alone. Seventy-one percent of the...

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X